Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) Invested Capital (2017 - 2025)

Inmune Bio's Invested Capital history spans 9 years, with the latest figure at $25.4 million for Q3 2025.

  • For Q3 2025, Invested Capital fell 38.36% year-over-year to $25.4 million; the TTM value through Sep 2025 reached $25.4 million, down 38.36%, while the annual FY2024 figure was $47.1 million, 0.51% down from the prior year.
  • Invested Capital for Q3 2025 was $25.4 million at Inmune Bio, down from $28.9 million in the prior quarter.
  • Across five years, Invested Capital topped out at $90.6 million in Q1 2022 and bottomed at $25.4 million in Q3 2025.
  • The 5-year median for Invested Capital is $50.7 million (2023), against an average of $54.3 million.
  • The largest annual shift saw Invested Capital surged 183.66% in 2021 before it crashed 43.18% in 2024.
  • A 5-year view of Invested Capital shows it stood at $80.2 million in 2021, then fell by 18.85% to $65.1 million in 2022, then fell by 27.29% to $47.3 million in 2023, then dropped by 0.51% to $47.1 million in 2024, then plummeted by 46.12% to $25.4 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Invested Capital are $25.4 million (Q3 2025), $28.9 million (Q2 2025), and $29.7 million (Q1 2025).